These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33336229)

  • 61. Diet and biomarkers of Alzheimer's disease: a systematic review and meta-analysis.
    Hill E; Goodwill AM; Gorelik A; Szoeke C
    Neurobiol Aging; 2019 Apr; 76():45-52. PubMed ID: 30682676
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease.
    Teuber-Hanselmann S; Rekowski J; Vogelgsang J; von Arnim C; Reetz K; Stang A; Jöckel KH; Wiltfang J; Esselmann H; Otto M; Tumani H; Herring A; Keyvani K
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):40-48. PubMed ID: 31371645
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial.
    Rosenberg A; Solomon A; Soininen H; Visser PJ; Blennow K; Hartmann T; Kivipelto M;
    Alzheimers Res Ther; 2021 Mar; 13(1):64. PubMed ID: 33766132
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
    Mattsson N; Lönneborg A; Boccardi M; Blennow K; Hansson O;
    Neurobiol Aging; 2017 Apr; 52():196-213. PubMed ID: 28317649
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Brain-Derived Exosomal Proteins as Effective Biomarkers for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Kim KY; Shin KY; Chang KA
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356604
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease.
    Boumenir A; Cognat E; Sabia S; Hourregue C; Lilamand M; Dugravot A; Bouaziz-Amar E; Laplanche JL; Hugon J; Singh-Manoux A; Paquet C; Dumurgier J
    Alzheimers Res Ther; 2019 Mar; 11(1):29. PubMed ID: 30922415
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease.
    Velickaite V; Giedraitis V; Ström K; Alafuzoff I; Zetterberg H; Lannfelt L; Kilander L; Larsson EM; Ingelsson M
    BMC Geriatr; 2017 Sep; 17(1):208. PubMed ID: 28886705
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin.
    Carro E; Bartolomé F; Bermejo-Pareja F; Villarejo-Galende A; Molina JA; Ortiz P; Calero M; Rabano A; Cantero JL; Orive G
    Alzheimers Dement (Amst); 2017; 8():131-138. PubMed ID: 28649597
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Cerebrospinal fluid amyloid beta and tau protein: biomarkers for Alzheimer's disease].
    Mandić G; Marković I; Ostojić M; Stojković T; Misirlić-Dencić S; Zivanović-Radnić T; Stefanović R; Bumbasirević M; Stefanova E; Kostić V
    Vojnosanit Pregl; 2008 Dec; 65(12):901-5. PubMed ID: 19160984
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease.
    Jaillard A; Vanhoutte M; Maureille A; Schraen S; Skrobala E; Delbeuck X; Rollin-Sillaire A; Pasquier F; Bombois S; Semah F
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):324-333. PubMed ID: 30155553
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
    J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Decreased salivary lactoferrin levels are specific to Alzheimer's disease.
    González-Sánchez M; Bartolome F; Antequera D; Puertas-Martín V; González P; Gómez-Grande A; Llamas-Velasco S; Herrero-San Martín A; Pérez-Martínez D; Villarejo-Galende A; Atienza M; Palomar-Bonet M; Cantero JL; Perry G; Orive G; Ibañez B; Bueno H; Fuster V; Carro E
    EBioMedicine; 2020 Jul; 57():102834. PubMed ID: 32586758
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update.
    Portelius E; Brinkmalm G; Pannee J; Zetterberg H; Blennow K; Dahlén R; Brinkmalm A; Gobom J
    Expert Rev Proteomics; 2017 Nov; 14(11):1007-1020. PubMed ID: 28942688
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease.
    Coart E; Barrado LG; Duits FH; Scheltens P; van der Flier WM; Teunissen CE; van der Vies SM; Burzykowski T;
    J Alzheimers Dis; 2015; 46(4):889-99. PubMed ID: 25869788
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis.
    Qu Y; Ma YH; Huang YY; Ou YN; Shen XN; Chen SD; Dong Q; Tan L; Yu JT
    Neurosci Biobehav Rev; 2021 Sep; 128():479-486. PubMed ID: 34245759
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.